Peripheral Neuropathy Market Growth Opportunities: Insights from 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Peripheral Neuropathy Market Expected To Expand Between 2025 And 2029?

The peripheral neuropathy market size has witnessed swift expansion in recent years. It is anticipated to rise from $4.09 billion in 2024 to $4.59 billion in 2025, achieving a compound annual growth rate (CAGR) of 12.2%. The growth observed in previous periods is largely due to the escalating prevalence of chronic conditions like diabetes, increased understanding of neuropathic pain management, a worldwide surge in the geriatric population, the development of healthcare infrastructure, the availability of dedicated treatment centers, governmental initiatives aimed at improving neurological healthcare services, and the increasing adoption of new treatment approaches.

The peripheral neuropathy market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $7.24 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.1%. Several factors will drive this growth during the forecast period, including the ongoing increase in chronic disease prevalence, especially diabetes and cancer, alongside progress in pharmacological treatments for neuropathic pain pathways. Furthermore, greater investment in research and development for novel treatment approaches, the incorporation of digital health tools for remote tracking and tailored management of neuropathic symptoms, a stronger emphasis on patient-focused care models, and enhanced availability of multidisciplinary healthcare services will contribute to this expansion. Key trends expected over this period encompass a rise in the uptake of personalized treatment strategies, the wider utilization of wearable devices for real-time monitoring of neuropathic symptoms and treatment efficacy, and the broadening of telemedicine services for virtual consultations and follow-ups. Additionally, the emergence of targeted therapies designed to address particular neuropathic pain pathways and mechanisms, breakthroughs in regenerative medicine, the adoption of digital therapeutics platforms for cognitive behavioral therapy and mindfulness interventions, and technological improvements in diagnostic tools for the early detection and ongoing monitoring of peripheral neuropathy are significant developments.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16507&type=smp

What Are The Top Growth Drivers Impacting The Peripheral Neuropathy Market Outlook?

The increasing incidence of diabetes is projected to fuel the expansion of the peripheral neuropathy market in the coming years. Diabetes is a chronic ailment marked by elevated glucose levels in the bloodstream, resulting from the body’s inability to produce or properly utilize insulin. This growing prevalence of diabetes is primarily attributable to factors such as increasing obesity rates, inactive lifestyles, and an aging demographic. Diabetes can lead to peripheral neuropathy by causing nerve damage due to persistently high blood sugar, manifesting in symptoms like pain, tingling, and numbness in the extremities. Effective management of blood sugar is crucial to prevent or slow the progression of this complication. For instance, in April 2023, a report published by The British Diabetic Association, a UK-based diabetes charity, stated that 4.3 million individuals in the UK are diagnosed with diabetes. Registration data for 2021-22 revealed an increase of 148,951 cases compared to 2020-21. Additionally, over 2.4 million people in the UK are identified as being at high risk of developing type 2 diabetes. Hence, the rising prevalence of diabetes is driving the growth of the peripheral neuropathy market.

What Are The Major Segment Categories Driving The Peripheral Neuropathy Market Growth?

The peripheral neuropathymarket covered in this report is segmented –

1) By Type: Chemotherapy-Induced; Diabetic; Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated; Idiopathic

2) By Diagnosis: Blood Test; Biopsy; Imaging; Other Diagnosis

3) By Treatment: Medications; Antidepressants; Anti-Seizure Medication; Pain Reliever; Topical Treatment; Therapies; Nerve Stimulation; Plasma Exchange; Physical Therapy; Other Treatments

4) By End-User: Hospitals; Clinics; Ambulatory Centers

Subsegments:

1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy; Platinum-Based Drug-Induced Neuropathy; Other Chemotherapy-Induced Neuropathies

2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy; Type 2 Diabetes-Induced Peripheral Neuropathy

3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy; AIDS-Related Peripheral Neuropathy

4) By Idiopathic: Acute Idiopathic Neuropathy; Chronic Idiopathic Neuropathy

What Trends Are Redefining The Peripheral Neuropathy Market Dynamics?

Leading firms within the peripheral neuropathy market are concentrating on creating sophisticated solutions, including point-of-care instruments, to enhance the diagnosis and treatment of this ailment. A quantitative point-of-care screening test for peripheral neuropathy serves as a diagnostic instrument designed for the swift identification of nerve damage in patients’ extremities, especially in diabetic individuals. As an example, in January 2023, NeuroMetrix Inc., a US-based manufacturer of non-invasive medical devices, introduced its DPNCheck 2.0 point-of-care device for the detection of peripheral neuropathy. This device employs nerve conduction technology to identify the systemic degradation of peripheral nerves, a process that can result in debilitating illnesses like diabetic peripheral neuropathy (DPN). It facilitates quick patient screening by quantitatively measuring peripheral nerve function, establishing it as a more efficient and precise instrument when contrasted with conventional techniques such as monofilament and tuning fork assessments.

Who Are The Prominent Global Companies Shaping The Peripheral Neuropathy Market?

Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Asahi Kasei Corporation, Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, ACI Limited, Lexicon Pharmaceuticals, Solasia Pharma KK, Helixmith Co. Ltd., PledPharma AB

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

What Regional Growth Trends Are Shaping The Peripheral Neuropathy Market Outlook?

North America was the largest region in the peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Peripheral Neuropathy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16507&type=smp

Browse Through More Reports Similar to the Global Peripheral Neuropathy Market 2025, By The Business Research Company

Nephrology And Urology Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nephrology-and-urology-devices-global-market-report

Injection Molding Machine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/injection-molding-machine-global-market-report

Gasoline Direct Injection Gdi Device Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gasoline-direct-injection-gdi-device-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795